Overview
Supernus Pharmaceuticals is a specialty CNS biopharmaceutical company with a portfolio of approved products for epilepsy, ADHD, and Parkinson's disease, including Oxtellar XR, Trokendi XR, Qelbree, and Gocovri. They focus on developing differentiated medicines for underserved neurological conditions.
More in Neuropharmaceuticals
Latest industry news
BlueWind Medical's Revi Extend Wins FDA Clearance, Extending Implant Life to 15 Years
2026-08-06 · Product
Neurofeedback Systems Market Eyes $2.95 Billion Valuation by 2035 as Clinical and Consumer Demand Converge
2026-08-05 · Industry
Smaller Neuromodulation Devices Are Reshaping the Competitive Landscape for TMS Providers
2026-08-04 · Industry
NIH-Backed Brain-Computer Device Restores Speech in Paralyzed Patient
2026-08-03 · Research
Company details
Category
💊 Neuropharmaceuticals
Location
Rockville, USA
Funding
Public · NASDAQ: SUPN
Website
www.supernus.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →